Business
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Deepak Sampath as a corporate advisor effective 30 May, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are thrilled to welcome Dr. Deepak Sam
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Deepak Sampath as a corporate advisor effective 30 May, 2025.","length":434,"tagName":"p"},{"type":"text","content":"Stephen Van Deventer, CEO of PreveCeutical, commented:","length":54,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Dr. Deepak Sampath to our Corporate Advisory Board. Deepak's extraordinary career, spanning over 25 years in molecular and cellular biology, pharmacology, and drug development, adds invaluable expertise to PrevCeutical's leadership team. His track record of advancing programs from discovery to clinical development and regulatory approval aligns seamlessly with our mission to deliver transformative therapies for metabolic and genetic disorders. We look forward to his insights as we continue to expand our impact in the life sciences sector."","length":591,"tagName":"p"},{"type":"text","content":"Dr. Deepak Sampath's Career Highlights:","length":43,"tagName":"p"},{"type":"text","content":"Dr. Sampath is a distinguished scientist and seasoned executive leader with extensive experience in small molecules, protein biologics, nucleic acids, and gene therapies. His leadership has driven numerous programs from early research and drug discovery into clinical trials and through regulatory approval for commercialization. Most notably, he has made significant contributions to the treatment of oncological diseases, including the FDA approval of venetoclax, a first-in-class BCL-2 selective inhibitor for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). His additional expertise spans the discovery and development of predictive biomarkers, translational research, target identification and validation. Dr. Sampath has also been instrumental in establishing strategic partnerships with academic institutions and industry leaders, ensuring the successful translation of cutting-edge science into therapeutic breakthroughs. Additionally, he has published 108 articles in peer-reviewed journals and...